Weight-loss drugs linked to longer survival in sleep apnea
Five-year survival was 95.1% among drug users, compared with 89.6% among non-users in a cohort of people with obstructive sleep apnea.

Our read
Populations- Studied:
- Cohort study of 136,782 patients with OSA, against non-users
- What changed:
- Five-year overall survival was higher among GLP-1RA users compared with non-users: 95.1% against 89.6%
- The catch:
- Drug users may have differed in underlying health or care beyond adjustment and matching
- In the record:
- The 15th paper on GIP/GLP-1 receptor agonists with results in people; 154 on record in all.
Editor of record: Boris Djordjevic · AgingResearch.News
Among 136,782 patients with obstructive sleep apnea, a condition that repeatedly blocks breathing during sleep, use of hormone-targeting drugs was linked to lower mortality in a retrospective observational cohort study. Patients averaged 59.1 years old, and 60.4% were male. They were diagnosed at three Mayo Clinic sites between January 2016 and December 2024. Of these, 24,205 received glucagon-like peptide-1 receptor agonists, drugs that activate receptors for this hormone.
After accounting for age, sex, diabetes and body mass index, a measure of weight relative to height, drug use was associated with lower mortality. The hazard ratio was 0.82, a relative measure of the death rate during follow-up. The link persisted in 17,601 matched pairs of users and non-users. It was consistent across age, sex and diabetes subgroups.
Why it matters
Obstructive sleep apnea is associated with premature death. The findings support evaluating these drugs as a potential way to help people with the condition live longer.
Caveats
Drug users may have differed in underlying health or care in ways that adjustment and matching did not capture. The findings were reported in a conference abstract.
The paper
Mayo Clinic Hospital; Mayo Clinic
AHA Scientific Sessions 2026 Abstract, Nov 2, 2026
Presented at AHA Scientific Sessions 2026, abstract 9325



Comments
Be the first to comment.